Peptide News Digest

#Inflammatory-Bowel-Disease

2 stories

Research · View digest

Shandong University Peptide Nanoparticle Based on the Macrophage Protein TIMD4 Eases Colitis in Mice

Shandong University researchers reported in PLOS Biology on October 21, 2026 that mice lacking TIMD4, a macrophage protein elevated in colon tissue from people with ulcerative colitis, developed worse chemically induced colitis with more monocytes entering the colon. They designed a peptide from TIMD4's intracellular region, T4(365-378), and packaged it in macrophage-targeted nanoparticles, which reduced inflammatory signaling and eased colitis, performed similarly to a CCR2-blocking drug, and worked better combined with anti-α4β7 or anti-TNF antibodies than either treatment alone. The results are from mice and cells.

Research · View digest

Medscape Publishes Emulated Randomized Trial Analysis Tuesday July 28, 2026 Using 2018-2023 US Insurance Claims Data Documenting That Adults With Stable Inflammatory Bowel Disease (IBD) and Comorbid Obesity or Diabetes Who Initiated Semaglutide or Tirzepatide Did Not Have a Lower Risk of IBD Relapse or Improved Safety Event Rates Versus Non-Initiators; Cohort 1 (Patients on 5-Aminosalicylates or No IBD-Specific Therapy) and Cohort 2 (Patients on Immunomodulators or Advanced Therapies) Both Reported No Benefit From GLP-1 Receptor Agonist Initiation on IBD Clinical Outcomes

Medscape published an emulated randomized trial analysis on Tuesday July 28, 2026 using US insurance claims data from 2018-2023 to test whether patients with stable inflammatory bowel disease (IBD) and comorbid obesity or diabetes benefit from initiating GLP-1 receptor agonist therapy alongside their ongoing IBD treatment. The researchers used a target trial emulation design comparing patients who initiated semaglutide or tirzepatide with patients who did not. Two cohorts were analyzed: Cohort 1 comprised patients on 5-aminosalicylates or no IBD-related therapy; Cohort 2 comprised patients on immunomodulators and/or advanced therapies (biologics or small molecules). Neither cohort showed a lower risk of IBD relapse or improved safety event rates among GLP-1 initiators. The analysis pushes back against the anti-inflammatory hypothesis advanced in preclinical GLP-1 receptor agonist literature (based on animal-model reductions in gut inflammation) and against the informal clinical assumption that IBD patients with obesity or diabetes may derive an anti-inflammatory benefit from initiating GLP-1 therapy. The clinical implication: prescribers should not initiate GLP-1 receptor agonist therapy in stable IBD patients for the purpose of improving IBD outcomes. GLP-1 initiation for obesity or diabetes in this population remains reasonable when the metabolic indication justifies it independently.